Alvotech (ALVO)

14.40 -0.11 (-0.76%) At close: 04:00PM EDT

Alvotech

9, Rue de Bitbourg
Luxembourg 1273
Luxembourg

https://www.alvotech.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 999

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Faysal Kalmoua	COO & Director	N/A	N/A	1976
Mr. Robert Wessman	CEO, Founder & Executive Chairman	740k	N/A	1970
Mr. Joel Morales	Chief Financial Officer	N/A	N/A	1978
Mr. Giedrius Zunda	Chief Technical Officer	N/A	N/A	N/A
Mr. Joseph E. McClellan	Chief Scientific Officer	N/A	N/A	1974
Ms. Tanya Zharov	General Counsel	N/A	N/A	1967
Ms. Jenny Sif Steingrimsdottir	Vice President of People & Culture	N/A	N/A	N/A
Mr. Anil Okay	Chief Commercial Officer	N/A	N/A	1986
Mr. Ming Li	Chief Strategy Officer	N/A	N/A	1977
Ms. Christina Siniscalchi	Chief Quality Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Corporate governance

Alvotech’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.